Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.290
+0.040 (1.78%)
At close: Aug 13, 2025, 4:00 PM
2.230
-0.060 (-2.62%)
Pre-market: Aug 14, 2025, 9:16 AM EDT
Aytu BioPharma Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Aytu BioPharma stock ranges from a low of $8.00 to a high of $12. The average analyst price target of $10 forecasts a 336.68% increase in the stock price over the next year.
Price Target: $10.00 (+336.68%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 1, 2025.
Analyst Ratings
The average analyst rating for Aytu BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +249.34% | Jul 1, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +424.02% | Jun 30, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +118.34% | Aug 9, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +773.36% | May 31, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $220 → $120 | Strong Buy | Maintains | $220 → $120 | +5,140.17% | Jul 21, 2022 |
Financial Forecast
Revenue This Year
70.46M
from 81.00M
Decreased by -13.02%
Revenue Next Year
71.20M
from 70.46M
Increased by 1.05%
EPS This Year
0.67
from -2.86
EPS Next Year
0.09
from 0.67
Decreased by -86.36%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 74.4M | 80.9M | 103.9M | |||
| Avg | 70.5M | 71.2M | 101.0M | |||
| Low | 66.0M | 61.3M | 97.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -8.2% | 14.8% | 46.0% | |||
| Avg | -13.0% | 1.1% | 41.8% | |||
| Low | -18.6% | -12.9% | 36.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.69 | 0.09 | 0.69 |
| Avg | 0.67 | 0.09 | 0.67 |
| Low | 0.65 | 0.09 | 0.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | -86.0% | 654.9% |
| Avg | - | -86.4% | 633.3% |
| Low | - | -86.9% | 604.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.